Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran.
Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Int J Nanomedicine. 2020 May 29;15:3877-3886. doi: 10.2147/IJN.S249942. eCollection 2020.
Vaccine formulation with appropriate adjuvants is an attractive approach to develop protective immunity against pathogens. Calcium phosphate nanoparticles (CaPNs) are considered as ideal adjuvants and delivery systems because of their great potential for enhancing immune responses. In the current study, we have designed nanoparticle-based vaccine candidates to induce immune responses and protection against and .
For this purpose, we used three antigens (FliC, 7α-HSDH, BhuA) and two multi-epitopes (poly B and poly T) absorbed by CaPNs. The efficacy of each formulation was evaluated by measuring humoral, cellular and protective responses in immunized mice.
The CaPNs showed an average size of about 90 nm with spherical shape and smooth surface. The CaPNs-adsorbed proteins displayed significant increase in cellular and humoral immune responses compared to the control groups. In addition, our results showed increased ratio of specific IgG2a (associated with Th1) to specific IgG1 (associated with Th2). Also, immunized mice with different vaccine candidate formulations were protected against 16M and 544, and showed same levels of protection as commercial vaccines ( Rev.1 and RB51) except for BhuA-CaPNs.
Our data support the hypothesis that these antigens absorbed with CaPNs could be effective vaccine candidates against and .
用适当的佐剂配制疫苗是开发针对病原体的保护性免疫的一种有吸引力的方法。磷酸钙纳米粒子(CaPNs)由于其增强免疫反应的巨大潜力,被认为是理想的佐剂和递送系统。在目前的研究中,我们设计了基于纳米颗粒的疫苗候选物,以诱导针对 和 的免疫反应和保护。
为此,我们使用了三种 抗原(FliC、7α-HSDH、BhuA)和两种多表位(多 B 和多 T)被 CaPNs 吸附。通过测量免疫小鼠的体液、细胞和保护反应来评估每种配方的功效。
CaPNs 的平均粒径约为 90nm,呈球形且表面光滑。与对照组相比,CaPNs 吸附的蛋白质显示出显著增加的细胞和体液免疫反应。此外,我们的结果显示,特异性 IgG2a(与 Th1 相关)与特异性 IgG1(与 Th2 相关)的比值增加。此外,用不同疫苗候选物配方免疫的小鼠对 16M 和 544 具有保护作用,并且除了 BhuA-CaPNs 外,其保护水平与商业疫苗(Rev.1 和 RB51)相同。
我们的数据支持了这样的假设,即这些被 CaPNs 吸附的抗原可以成为针对 和 的有效疫苗候选物。